



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Frontpro 28 mg Chewable Tablets for Dogs >4–10 kg Vm 04491/5011

• 13 April 2023	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
• 23 August 2022	Change in name of manufacturer of the finished product.
• 25 April 2022	Increase in batch size of the active substance.
• 25 April 2022	Change in composition of the immediate packaging for the active substance.
• 15 February 2022	Deletion of a supplier of packaging components or devices.
• 02 September 2021	Change in shape or dimensions of the container or closure (immediate packaging). Minor change in the manufacturing process of the finished product. Deletion of a non-significant specification parameter of an excipient.
• 25 March 2021	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.